Resultats de la cerca - Michael Boxer

  • Mostrar 1 - 9 resultats de 9
Refinar resultats
  1. 1
    The risk of Parkinson's disease in type 1 Gaucher disease

    The risk of Parkinson's disease in type 1 Gaucher disease per Gilberto Bultron, Katherine Kacena, Daniel S. Pearson, Michael Boxer, Ruhua Yang, Swati Sathe, Gregory M. Pastores, Pramod K. Mistry

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

    Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program per James B. Bussel, Donald M. Arnold, Michael Boxer, Nichola Cooper, Jiřı́ Mayer, Hany Zayed, Sandra Tong, Anne‐Marie Duliège

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

    An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia per Jeff P. Sharman, Michael Hawkins, Kathryn S. Kolibaba, Michael Boxer, Leonard M. Klein, Meihua Wu, Jing Hu, Steve Abella, Chris Yasenchak

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long‐term outcomes of therapy

    Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long‐term outcomes of therapy per Sarah M. Lo, Jun Liu, F. Chen, Gregory M. Pastores, James A. Knowles, Michael Boxer, Kirk Aleck, Pramod K. Mistry

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients

    The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients per Tamar H. Taddei, Katherine Kacena, Mei Yang, Ruhua Yang, Advitya Malhotra, Michael Boxer, Kirk Aleck, Gad Rennert, Gregory M. Pastores, Pramod K. Mistry

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia

    Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia per Ralph V. Boccia, Nichola Cooper, Waleed Ghanima, Michael Boxer, Quentin A. Hill, Michelle Sholzberg, Michael D. Tarantino, Leslie Todd, Sandra Tong, James B. Bussel

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

    Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia per John C. Byrd, Joseph M. Flynn, Thomas J. Kipps, Michael Boxer, Kathryn S. Kolibaba, David Carlile, Guenter Fingerle-Rowson, Nicola Tyson, Jamie Hirata, Jeff P. Sharman

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study

    Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study per David J. Kuter, Kerry A. Rogers, Michael Boxer, Michael Y. Choi, Richy Agajanian, Donald M. Arnold, Catherine M. Broome, Joshua J. Field, Irina Murakhovskaya, Robert P. Numerof, Sandra Tong

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

    Comprehensively understanding fatigue in patients with myeloproliferative neoplasms per Robyn M. Scherber, Heidi E. Kosiorek, Zhenya Senyak, Amylou C. Dueck, Matthew M. Clark, Michael Boxer, Holly L. Geyer, Archie McCallister, Mary Cotter, Barbara Van Husen, Claire Harrison, Ruben A. Mesa

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: